Our conversation with Javier was a deep dive into the unique challenges of the biotech industry, the incredible potential of AI, and the unwavering resolve required to build a company from the ground up.

The Pauling Principle and the Mission of Pauling.AI

Javier’s company, Pauling.AI, is named after the legendary chemist and two-time Nobel Prize winner, Linus Pauling. This name not only honors a scientific giant but also represents the core principle of the company's work. Javier also hosts a podcast called The Pauling Principle, where he explores the intersection of AI, biotech, and drug discovery by speaking with other experts in these fields.

Pauling.AI's mission is to democratize early-stage drug discovery, a process that is notoriously expensive and time-consuming. Javier explained that their ideal customers are early-stage biotech companies trying to find novel molecules for their therapies. These companies often have to choose between raising millions to hire an in-house team or contracting a Contract Research Organization (CRO) to handle the complex work of computational chemistry.

Pauling.AI has built an AI agent that automates much of this initial work, providing an alternative that is not only faster and cheaper but also aims for equal or higher quality results. By making this critical first step more accessible, they're helping scientists get started on their groundbreaking work more quickly and efficiently.

Post-COVID Biotech: A Pendulum of Investment

The COVID-19 pandemic brought the biotech industry into the global spotlight. Javier recalled how companies like Moderna and BioNTech, with their novel mRNA technology, were able to develop a vaccine in record time. This unprecedented achievement showcased the potential for rapid drug development when the right science and technology converge with a pressing global need.

However, Javier noted that the investment boom that followed has since reversed. While there was a huge surge in funding during the height of the pandemic, the biotech sector is now experiencing a downturn. He called this a "pendulum" effect, where investment swings from one extreme to the other. The unfortunate consequence of this current downturn, he explained, is that it will likely result in fewer new medicines being discovered five years from now, a sad reality for the future of healthcare.

The Future of AI in Life Sciences: Agentic Behavior and Integration

Javier offered a compelling vision for the future of AI, speculating on how it will transform the life sciences and beyond. He believes that we'll see AI systems become more integrated and autonomous.

Key trends he identified include:

• Smarter Language Models: The continuous improvement of large language models will make them more powerful and versatile.
• Increased Automation: As the cost of labor rises, companies will increasingly turn to AI to automate tasks across various sectors, from marketing to customer service.
• Seamless Integration: AI systems will become more deeply integrated into our existing tools, connecting everything from your email to your spreadsheets to create a more cohesive workflow.
• Agentic Behavior: The most significant shift, according to Javier, will be the rise of AI agents. Unlike a simple language model that provides a single response, an AI agent can perform a complex sequence of actions on its own to complete a mission. For example, an agent could download a tool, install it, record a video, save it, and then share it—all without human intervention. This is precisely the type of system Pauling.AI is building for drug discovery.

The Biggest Challenge: Biology's Complexity

When discussing the challenges of scaling a company at the intersection of AI and biotech, Javier was unequivocal: the main problem is biology itself.

Even with the most sophisticated computer simulations and extensive research, biology is incredibly complex and unpredictable. This is why drug discovery is a long, difficult, and expensive process. He drew a powerful parallel between drug development and filmmaking: the cost isn't in the final product (the pill or the movie file), but in the billions of dollars and years of effort required to create it in the first place.

This complexity, however, is where AI offers its greatest promise. By using AI tools, Javier believes the success rate of drug discovery—which is currently a mere 1-3%—could be dramatically increased to 5-15%. The ultimate positive outcome of this would be a much-needed increase in the number of medicines available for a wide range of diseases.

A Guiding Principle: The Power of Perseverance

Javier concluded our conversation with a powerful piece of advice for entrepreneurs, drawn from his own experience of transitioning from a massive corporation to a startup. In a big company, momentum carries the business forward, and individual impact is often a small part of a larger machine. In a startup, however, the reverse is true.

His best advice? "Just keep going."

In a startup, there are constant headwinds, and it can feel like you're banging your head against a wall. The energy and impetus must come from the founders, and there will be times when you need to consciously remind yourself to persevere. For Javier, this unwavering determination to keep pushing forward, no matter the obstacles, is the single most important quality for an entrepreneur.